Hereditary Colorectal Cancer Syndromes: Familial Adenomatous Polyposis and Lynch Syndrome

Surgical Clinics of North America

Volumn 88, Issue 4, 2008, Pages 819-844

  Al Sukhni, Wigdan ^a,b   Aronson, Melyssa ^c   Gallinger, Steven ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

^c Zane Cohen Digestive Diseases Clinical Research Center   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA INTERFERON; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DACARBAZINE; DOXORUBICIN; FLUOROURACIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRINOTECAN; MESALAZINE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; OXALIPLATIN; PLACEBO; ROFECOXIB; URSODEOXYCHOLIC ACID; VINBLASTINE; VITAMIN;

ADENOMATOUS POLYP; AUTOSOMAL DOMINANT INHERITANCE; CANCER GENETICS; CANCER RISK; CANCER SCREENING; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; COLON RESECTION; COLONOSCOPY; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; DESMOID TUMOR; DISEASE ASSOCIATION; FAMILIAL CANCER; GASTROINTESTINAL SYMPTOM; GENE MUTATION; GENETIC ANALYSIS; HUMAN; ILEOSTOMY; NONHUMAN; PRIORITY JOURNAL; PROCTOCOLECTOMY; PROGNOSIS; QUALITY OF LIFE; REVIEW;

ADENOMATOUS POLYPOSIS COLI; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; DIAGNOSIS, DIFFERENTIAL; GENETIC PREDISPOSITION TO DISEASE; HUMANS;

EID: 47949122502     PISSN: 00396109     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.suc.2008.04.012     Document Type: Review

References (124)

1. Gryfe R. Clinical implications of our advancing knowledge of colorectal cancer genetics: inherited syndromes, prognosis, prevention, screening and therapeutics. Surg Clin North Am 86 4 (2006) 787-817
2. Bulow S., Berk T., and Neale K. The history of familial adenomatous polyposis. Fam Cancer 5 3 (2006) 213-220
3. Senda T., Iizuka-Kogo A., Onouchi T., et al. Adenomatous polyposis coli plays multiple roles in the intestinal and colorectal epithelia. Med Mol Morphol 40 2 (2007) 68-81
4. Merg A., Lynch H., Lynch J., et al. Hereditary colon cancer-Part I. Curr Probl Surg 42 4 (2005) 195-256
5. Brensinger J.D., Laken S.J., Luce M.C., et al. Variable phenotype of familial adenomatous polyposis in pedigrees with 3′ mutation in the APC gene. Gut 43 (1998) 548-552
6. Kashiwagi H., and Spigelman A.D. Gastroduodenal lesions in familial adenomatous polyposis. Surg Today 30 8 (2000) 675-682
7. Galiatsatos P., and Foulkes W.D. Familial adenomatous polyposis. Am J Gastroenterol 101 2 (2006) 385-398
8. Spigelman A.D., Williams C.B., Talbot I.C., et al. Upper gastrointestinal cancer in patients with familial adenomatous polyposis. Lancet 2 (1989) 783-785
9. Saurin J.C., Guknecht C., Napoleon B., et al. Surveillance of duodenal adenomas in familial adenomatous polyposis reveals high cumulative risk of advanced disease. J Clin Oncol 22 3 (2004) 493-498
10. Sellner F. Investigations on the significance of the adenoma-carcinoma sequence in the small bowel. Cancer 66 4 (1990) 702-715
11. Groves C.J., Saunders B.P., Spigelman A.D., et al. Duodenal cancer in patients with familial adenomatous polyposis (FAP): results of a 10 year prospective study. Gut 50 5 (2002) 636-641
12. Bjork J., Akerbrant H., Iselius L., et al. Periampullary adenomas and adenocarcinomas in familial adenomatous polyposis: cumulative risks and APC gene mutations. Gastroenterology 121 5 (2001) 1127-1135
13. Heiskanen I., Kellokumpu I., and Jarvinen H. Management of duodenal adenomas in 98 patients with familial adenomatous polyposis. Endoscopy 31 6 (1999) 412-416
14. Sanabria J.R., Croxford R., Berk T.C., et al. Familial segregation in the occurrence and severity of periampullary neoplasms in familial adenomatous polyposis. Am J Surg 171 1 (1996) 136-140
15. Church J.M., McGannon E., Hull-Boiner S., et al. Gastroduodenal polyps in patients with familial adenomatous polyposis. Dis Colon Rectum 35 12 (1992) 1170-1173
16. Burt R.W. Gastric fundic gland polyps. Gastroenterology 125 5 (2003) 1462-1469
17. Mabrut J.Y., Romagnoli R., Collard J.M., et al. Familial adenomatous polyposis predisposes to pathologic exposure of the stomach to bilirubin. Surgery 140 5 (2006) 818-823
18. Iwama T., Mishima Y., and Utsunomiya J. The impact of familial adenomatous polyposis on the tumorigenesis and mortality at the several organs. Its rational treatment. Ann Surg 217 2 (1993) 101-108
19. Kadmon M., Tandara A., and Herfarth C. Duodenal adenomatosis in familial adenomatous polyposis coli. A review of the literature and results from the Heidelberg Polyposis Register. Int J Colorectal Dis 16 (2001) 63-75
20. Jones I.T., Jagelman D.G., Fazio V.W., et al. Desmoid tumors in familial polyposis coli. Ann Surg 204 1 (1986) 94-97
21. Durno C., Mongo N., Bapat B., et al. Does early colectomy increase desmoid risk in familial adenomatous polyposis?. Clin Gastroenterol Hepatol 5 10 (2007) 1190-1194
22. Herraiz M., Barbesino G., Faquin W., et al. Prevalence of thyroid cancer in familial adenomatous polyposis syndrome and the role of screening ultrasound examinations. Clin Gastroenterol Hepatol 5 3 (2007) 367-373
23. Truta B., Allen B.A., Conrad P.G., et al. Genotype and phenotype of patients with both familial adenomatous polyposis and thyroid carcinoma. Fam Cancer 2 2 (2003) 95-99
24. Aretz S., Koch A., Uhlhaas S., et al. Should children at risk for familial adenomatous polyposis be screened for hepatoblastoma and children with apparently sporadic hepatoblastoma be screened for APC germline mutations?. Pediatr Blood Cancer 47 6 (2006) 811-818
25. Hamilton S.R., Liu B., Parsons R.E., et al. The molecular basis of Turcot's syndrome. N Engl J Med 332 13 (1995) 839-847
26. Gupta C., and Mazzara P.F. High-grade pancreatic intraepithelial neoplasia in a patient with familial adenomatous polyposis. Arch Pathol Lab Med 129 11 (2005) 1398-1400
27. Chetty R., Salahshor S., Bapat B., et al. Intraductal papillary mucinous neoplasm of the pancreas in a patient with attenuated familial adenomatous polyposis. J Clin Pathol 58 1 (2005) 97-101
28. Maire F., Hammel P., Terris B., et al. Intraductal papillary and mucinous pancreatic tumour: a new extracolonic tumour in familial adenomatous polyposis. Gut 51 3 (2002) 446-449
29. DiMagno E.P. Pancreatic cancer: clinical presentation, pitfalls and early clues. Ann Oncol 10 S4 (1999) 140-142
30. Narayan S., and Roy D. Role of APC and DNA mismatch repair genes in the development of colorectal cancers. Mol Cancer 2 (2003) 41-55
31. Caspari R., Friedl W., Mandl M., et al. Familial adenomatous polyposis: mutation at codon 1309 and early onset of colon cancer. Lancet 343 8898 (1994) 629-632
32. Soravia C., Berk T., Madlensky L., et al. Genotype-phenotype correlations in attenuated adenomatous polyposis coli. Am J Hum Genet 62 (1998) 1290-1301
33. Couture J., Mitri A., Legace R., et al. A germline mutation at the extreme 3′ end of the APC gene results in a severe desmoid phenotype and is associated with overexpression of beta-catenin in the desmoid tumour. Clin Genet 57 3 (2000) 205-212
34. Caspari R., Olschwang S., Friedl W., et al. Familial adenomatous polyposis: desmoid tumors and lack of ophthalmic lesions (CHRPE) associated with APC mutations beyond codon 1444. Hum Mol Genet 4 (1995) 337-340
35. Nieuwenhuis M.H., and Vasen H.F. Correlations between mutation site in APC and phenotype of familial adenomatous polyposis (FAP): a review of the literature. Crit Rev Oncol Hematol 61 (2007) 153-161
36. Friedl W., Caspari R., Sengteller M., et al. Can APC mutation analysis contribute to therapeutic decisions in familial adenomatous polyposis? Experience from 680 FAP families. Gut 48 (2001) 515-521
37. Michils G., Tejpar S., Thoelen R., et al. Large deletions of the APC gene in 15% of mutation-negative patients with classical polyposis (FAP): a Belgian study. Hum Mutat 25 (2005) 125-134
38. Al-Tassan N., Chmiel N.H., Maynard J., et al. Inherited variants of MYH associated with somatic G:C→T:A mutations in colorectal tumors. Nat Genet 30 (2002) 227-232
39. Chow E., Thirlwell C., Macrae F., et al. Colorectal cancer and inherited mutations in base-excision repair. Lancet Oncol 5 10 (2004) 600-606
40. Farrington S.M., Tenesa A., Barnetson R., et al. Germline susceptibility to colorectal cancer due to base-excision repair gene defects. Am J Hum Genet 77 (2005) 112-119
41. Russell A.M., Zhang J., Luz J., et al. Prevalence of MYH germline mutations in Swiss APC mutation-negative polyposis patients. Int J Cancer 118 8 (2006) 1937-1940
42. Croitoru M.E., Cleary S.P., Monga N., et al. Germline MYH mutations in a clinic-based series of Canadian multiple colorectal adenoma patients. J Surg Oncol 95 6 (2007) 499-506
43. David S., O'Shea Y., and Kunda S. Base-excision repair of oxidative DNA damage. Nature 447 7147 (2007) 941-950
44. Balaguer F., Castellvi-Bel S., Castells A., et al. Identification of MYH mutation carriers in colorectal cancer: a multicenter, case-control, population-based study. Clin Gastroenterol Hepatol 5 3 (2007) 379-387
45. Bouguen G., Manfredi S., Blayau M., et al. Colorectal adenomatous polyposis associated with MYH mutations: genotype & phenotype characteristics. Dis Colon Rectum 50 10 (2007) 1612-1617
46. Jenkins M.A., Croitoru M.E., Monga N., et al. Risk of colorectal cancer in monoallelic and biallelic carriers of MYH mutations: a population-based case-family study. Cancer Epidemiol Biomarkers Prev 15 2 (2006) 312-314
47. Cheadle J.P., and Sampson J.R. MUTYH-associated polyposis-from defect in base excision repair to clinical genetic testing. DNA Repair (Amst) 6 3 (2007) 274-279
48. Aretz S., Stienen D., Friedrichs N., et al. Somatic APC mosaicism: a frequent cause of FAP. Hum Mutat 28 10 (2007) 985-992
49. Bisgaard M.L., Fenger K., Bulow S., et al. Familial adenomatous polyposis (FAP): frequency, penetrance, and mutation rate. Hum Mutat 3 (1994) 121-125
50. Schwab A., Tuohy T.M., Condie M., et al. Gonadal mosaicism and familial adenomatous polyposis. Fam Cancer 7 (2008) 173-177
51. Winawer S., Fletcher R., Rex D., et al. Colorectal cancer screening and surveillance: clinical guidelines and rationale-update based on new evidence. Gastroenterology 124 2 (2003) 544-560
52. Johnson J.C., DiSario J.A., and Grady W.M. Surveillance and treatment of periampullary and duodenal adenomas in familial adenomatous polyposis. Curr Treat Options Gastroenterol 7 2 (2004) 79-89
53. Gallagher M.C., Phillips R.K., and Bulow S. Surveillance and management of upper gastrointestinal disease in familial adenomatous polyposis. Fam Cancer 5 3 (2006) 263-273
54. Burke C.A., Santisi J., Church J., et al. The utility of capsule endoscopy small bowel surveillance in patients with polyposis. Am J Gastroenterol 100 7 (2005) 1498-1502
55. Wong R.F., Tuteja A.K., Haslem D.S., et al. Video capsule endoscopy compared with standard endoscopy for the evaluation of small-bowel polyps in persons with familial adenomatous polyposis (with video). Gastrointest Endosc 64 4 (2006) 530-537
56. Cetta F., Montalto G., Gori M., et al. Germline mutations of the APC gene in patients with familial adenomatous polyposis-associated thyroid carcinoma: results from a European cooperative study. J Clin Endocrinol Metab 85 1 (2000) 286-292
57. Church J. In which patients do I perform IRA, and why?. Fam Cancer 5 (2006) 237-240
58. De Cosse J.J., Bülow S., Neale K., et al. Rectal cancer risk in patients treated for familial adenomatous polyposis. The Leeds Castle Polyposis Group. Br J Surg 79 12 (1992) 1372-1375
59. Bulow C., Vasen H., Jarvinen H., et al. Ileorectal anastomosis is appropriate for a subset of patients with familial adenomatous polyposis. Gastroenterology 119 6 (2000) 1454-1460
60. Guillem J.G., Wood W.C., Moley J.F., et al. ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes. Ann Surg Oncol 13 10 (2006) 1296-1321
61. Church J., Burke C., McGannon E., et al. Risk of rectal cancer in patients after colectomy and ileorectal anastomosis for familial adenomatous polyposis: a function of available surgical options. Dis Colon Rectum 46 9 (2003) 1175-1181
62. Church J., and Simmang C. Standards Task Force; American Society of Colon and Rectal Surgeons; Collaborative Group of the Americas on Inherited Colorectal Cancer and the Standards Committee of The American Society of Colon and Rectal Surgeons. Practice parameters for the treatment of patients with dominantly inherited colorectal cancer (familial adenomatous polyposis and hereditary nonpolyposis colorectal cancer). Dis Colon Rectum 46 (2003) 1001-1012
63. Valanzano R., Ficari F., Curia M.C., et al. Balance between endoscopic and genetic information in the choice of ileorectal anastomosis for familial adenomatous polyposis. J Surg Oncol 95 1 (2007) 28-33
64. Kartheuser A., Stangherlin P., Brandt D., et al. Restorative proctocolectomy and ileal pouch-anal anastomosis for familial adenomatous polyposis revisited. Fam Cancer 5 3 (2006) 241-260
65. Chambers W.M., and McC Mortensen N.J. Should ileal pouch-anal anastomosis include mucosectomy?. Colorectal Dis 9 5 (2007) 384-392
66. Zhang H., Hu S., Zhang G., et al. Laparoscopic versus open proctocolectomy with ileal pouch-anal anastomosis. Minim Invasive Ther Allied Technol 16 3 (2007) 187-191
67. Alarcon F.J., Burke C.A., Church J.M., et al. Familial adenomatous polyposis. Efficacy of endoscopic and surgical treatment for advanced duodenal adenomas. Dis Colon Rectum 42 (1999) 1533-1536
68. Brosens L.A., Keller J.J., Offerhaus G.J., et al. Prevention and management of duodenal polyps in familial adenomatous polyposis. Gut 54 7 (2005) 1034-1043
69. Dixon E., Vollmer C.M., Sahajpal A., et al. Transduodenal resection of peri-ampullary lesions. World J Surg 29 5 (2005) 649-652
70. Gallagher M., Shankar A., Groves C., et al. Pylorus-preserving pancreaticoduodenectomy for advanced duodenal disease in familial adenomatous polyposis. Br J Surg 91 9 (2004) 1157-1164
71. Imamura M., Komoto I., Doi R., et al. New pancreas-preserving total duodenectomy technique. World J Surg 29 2 (2005) 203-207
72. Lev D., Kotilingam D., Wei C., et al. Optimizing treatment of desmoid tumors. J Clin Oncol 25 13 (2007) 1785-1791
73. Latchford A.R., Sturt N.J., Neale K., et al. A 10-year review of surgery for desmoid disease associated with familial adenomatous polyposis. Br J Surg 93 10 (2006) 1258-1264
74. Sakorafas G.H., Nissotakis C., and Peros G. Abdominal desmoid tumors. Surg Oncol 16 2 (2007) 131-142
75. Clark S.K., Neale K.F., Landgrebe J.C., et al. Desmoid tumours complicating familial adenomatous polyposis. Br J Surg 86 (1999) 1185-1189
76. Khor T.O., Cheung W.K., Prawan A., et al. Chemoprevention of familial adenomatous polyposis in Apc(Min/+) mice by phenethyl isothiocyanate (PEITC). Mol Carcinog 47 5 (2007) 321-325
77. Shen G., Khor T.O., Hu R., et al. Chemoprevention of familial adenomatous polyposis by natural dietary compounds sulforaphane and dibenzoylmethane alone and in combination in ApcMin/+ mouse. Cancer Res 67 20 (2007) 9937-9944
78. Steinbach G., Lynch P.M., Phillips R.K., et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342 (2000) 1946-1952
79. Phillips R.K., Wallace M.H., Lynch P.M., et al. A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. Gut 50 6 (2002) 857-860
80. Higuchi T., Iwama T., Yoshinaga K., et al. A randomized, double-blind, placebo-controlled trial of the effects of rofecoxib, a selective cyclooxygenase-2 inhibitor, on rectal polyps in familial adenomatous polyposis patients. Clin Cancer Res 9 13 (2003) 4756-4760
81. Spychalski M., Dizki L., and Dizki A. Chemoprevention of colorectal cancer - a new target needed?. Colorectal Dis 9 5 (2007) 397-401
82. Bresalier R.S., Sandler R.S., Quan H., et al., Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352 (2005) 1092-1102
83. Burn J. Invited commentary. Fam Cancer 5 (2006) 295-296
84. Merg A., Lynch H.T., Lynch J.F., et al. Hereditary colorectal cancer-part II. Curr Probl Surg 42 5 (2005) 267-333
85. Jass J.R. Hereditary non-polyposis colorectal cancer: the rise and fall of a confusing term. World J Gastroenterol 12 31 (2006) 4943-4950
86. Lynch H.T., Boland C.R., Gong G., et al. Phenotypic and genotypic heterogeneity in the Lynch syndrome: diagnostic, surveillance and management implications. Eur J Hum Genet 14 4 (2006) 390-402
87. Vasen H. Review article: the Lynch syndrome (hereditary nonpolyposis colorectal cancer). Aliment Pharmacol Ther 26 S2 (2007) 113-126
88. Paraf F., Jothy S., and Van Meir E.G. Brain tumor-polyposis syndrome: two genetic diseases?. J Clin Oncol 15 7 (1997) 2744-2758
89. Lindor N.M., Rabe K., Petersen G.M., et al. Lower cancer incidence in Amsterdam-I criteria families without mismatch repair deficiency: familial colorectal cancer type X. JAMA 293 16 (2005) 1979-1985
90. Vasen H.F., Moslein G., Alonso A., et al. Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer). J Med Genet 44 6 (2007) 353-362
91. Alarcon F., Lasset C., Carayol J., et al. Estimating cancer risk in HNPCC by the GRL method. Eur J Hum Genet 15 (2007) 831-836
92. Vasen H.F., Watson P., Mecklin J.P., et al. The epidemiology of endometrial cancer in hereditary nonpolyposis colorectal cancer. Anticancer Res 14 4B (1994) 1675-1678
93. van den B.M., van den H.M., Jongejan E., et al. More differences between HNPCC-related and sporadic carcinomas from the endometrium as compared to the colon. Am J Surg Pathol 28 (2004) 706-711
94. Watson P., Butzow R., Lynch H.T., et al. The clinical features of ovarian cancer in hereditary nonpolyposis colorectal cancer. Gynecol Oncol 82 2 (2001) 223-228
95. ten Kate G.L., Kleibeuker J.H., Nagengast F.M., et al. Is surveillance of the small bowel indicated for Lynch syndrome families?. Gut 56 9 (2007) 1198-1201
96. Boland C.R., Koi M., Chang D.K., et al. The biochemical basis of microsatellite instability and abnormal immunohistochemistry and clinical behaviour in Lynch Syndrome: from bench to bedside. Fam Cancer 7 1 (2007) 41-52
97. Boland C.R., Thibodeau S.N., Hamilton S.R., et al. A national cancer institute workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 58 (1998) 5248-5257
98. Hampel H., Frankel W.L., Martin E., et al. Screening for Lynch syndrome. N Engl J Med 66 15 (2005) 7810-7817
99. Burgart L.J. Testing for defective DNA mismatch repair in colorectal carcinoma: a practical guide. Arch Pathol Lab Med 129 11 (2005) 1385-1389
100. Hitchins M.P., Wong J.J., Suthers G., et al. Inheritance of a cancer-associated MLH1 germ-line epimutation. N Engl J Med 356 7 (2007) 697-705
101. Jass J.R. Hereditary and DNA methylation in colorectal cancer. Gut 56 1 (2007) 154-155
102. Rahner N., Friedrichs N., Steinke V., et al. Coexisting somatic promoter hypermethylation and pathogenic MLH1 germline mutation in Lynch syndrome. J Pathol 214 (2008) 10-16
103. Loughrey M.B., Waring P.M., Tan A., et al. Incorporation of somatic BRAF mutation testing into an algorithm for the investigation of hereditary non-polyposis colorectal cancer. Fam Cancer 6 3 (2007) 301-310
104. Barnetson R.A., Tenesa A., Farrington S.M., et al. Identification and survival of carriers of mutations in DNA mismatch-repair genes in colon cancer. N Engl J Med 354 26 (2006) 2751-2763
105. Chen S., Wang W., Lee S., et al. Prediction of germline mutations and cancer risk in the Lynch syndrome. JAMA 296 12 (2006) 1479-1487
106. Geary J., Sasieni P., Houlston R., et al. Gene-related cancer spectrum in familial with hereditary non-polyposis colorectal cancer (HNPCC). Fam Cancer 7 (2008) 163-172
107. Smith L., Tesoriero A., Mead L., et al. Large genomic alterations in hMSH2 and hMLH1 in early-onset colorectal cancer; identification of a large complex de novo hMLH1 alteration. Clin Genet 70 (2006) 250-252
108. Gallinger S., Aronson M., Shayan K., et al. Gastrointestinal cancers and neurofibromatosis type 1 features in children with a germline homozygous MLH1 mutation. Gastroenterology 126 2 (2004) 576-585
109. Jarvinen H.J., Aarnio M., Mustonen H., et al. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 118 (2000) 829-834
110. Mecklin J.P., Aarnio M., Laara E., et al. Development of colorectal tumors in colonoscopic surveillance in Lynch syndrome. Gastroenterology 133 4 (2007) 1093-1098
111. Renkonen-Sinisalo L., Butzow R., Leminen A., et al. Surveillance for endometrial cancer in hereditary nonpolyposis colorectal cancer syndrome. Int J Cancer 120 (2007) 821-824
112. Chen L., Yang K., Little S., et al. Gynecologic cancer prevention in Lynch syndrome/hereditary nonpolyposis colorectal cancer families. Obstet Gynecol 110 1 (2007) 18-25
113. Lindor N.M., Petersen G.M., Hadley D.W., et al. Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review. JAMA 296 12 (2006) 1507-1517
114. de Vos tot Nederveen Cappel W.H., Buskens E., van Duijvendijk P., et al. Decision analysis in the surgical treatment of colorectal cancer due to a mismatch repair gene defect. Gut 52 (2003) 1752-1755
115. Jenkins M.A., Baglietto L., Dowty J.G., et al. Cancer risks for mismatch repair gene mutation carriers: a population-based early onset case-family study. Clin Gastroenterol Hepatol 4 4 (2006) 489-498
116. Schmeler K.M., Lynch H.T., Chen L.M., et al. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med 354 3 (2006) 261-269
117. Burn J. Chemoprevention in hereditary colorectal cancer: where are we headed? In: 11th Annual Meeting of the Collaborative Group of the Americas on Inherited Colorectal Cancer. La Jolla: October 21-22, 2007.
118. Carethers J.M., Chauhan D.P., Fink D., et al. Mismatch repair proficiency and in vitro response to 5-fluorouracil. Gastroenterology 117 (1999) 123-131
119. Ribic C.M., Sargent D.J., Moore M.J., et al. Tumor microsatellite instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 349 (2003) 247-257
120. de Vos tot Nederveen Cappel W.H., Meulenbeld H.J., Kleibeuker J.H., et al. Survival after adjuvant 5-FU treatment for Stage III colon cancer in hereditary nonpolyposis colorectal cancer. Int J Cancer 109 (2004) 468-471
121. Des Guetz G., Mariani P., Cucherousset J., et al. Microsatellite instability and sensitivity to FOLFOX treatment in metastatic colorectal cancer. Anticancer Res 27 4C (2007) 2715-2719
122. Magrini R., Bhonde M.R., Hanski M.L., et al. Cellular effects of CPT-11 on colon carcinoma cells: dependence on p53 and hMLH1 status. Int J Cancer 101 (2002) 23-31
123. Fallik D., Borrini F., Boige V., et al. Microsatellite instability is a predictive factor of the tumor response to irinotecan in patients with advanced colorectal cancer. Cancer Res 63 (2003) 5738-5744
124. Charara M., Edmonston T.B., Burkholder S., et al. Microsatellite status and cell cycle associated markers in rectal cancer patients undergoing combined regimen of 5-FU and CPT-11 chemotherapy and radiotherapy. Anticancer Res 24 5B (2004) 3161-3167